Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMT101 + docetaxel
- Development stage
- Unknown
- Lead developer
- Shanghai Jinmante Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JMT101 + docetaxel is an investigational combination drug regimen consisting of JMT101, a fully humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and docetaxel, a taxane-class chemotherapeutic agent that stabilizes microtubules and inhibits cell division. JMT101 inhibits EGFR signaling through extracellular domain binding, receptor downregulation, and induces antibody-dependent cellular cytotoxicity by engaging immune effector cells. Docetaxel exerts cytotoxic effects via microtubule stabilization, blocking mitosis and promoting apoptosis of rapidly dividing cancer cells. This combination is under clinical evaluation for its antitumor efficacy and safety in advanced solid tumors, including colorectal cancer and potentially other EGFR-driven cancers[1][5].
- Brand names
- Taxotere
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on JMT101 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMT101 + docetaxel.